BATM Advanced Communications (BATM), a diagnostics business has received licence from China Food and Drug Administration to import, market and sell its diagnostic kit for hepatitis C virus (HCV) in China.

The diagnostic kit identifies by detecting antibodies to the virus using an ELISA screen.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

BATM CEO Dr Zvi Marom said: "China is the world’s largest market for hepatitis C diagnostics, and we believe that this approval will pave the way for the granting of licences for several more reagents that we have submitted for approval.

"The diagnostics business is focused on developing products for small to mid-size laboratories, including advanced genomic solutions that are being introduced to the market."

"Hepatitis C disease currently has no vaccine and it is estimated to kill approximately 350,000-500,000 every year, a number far greater than the recent tragedy spread by the Ebola virus.

"Our ambition is to ensure that the diagnosis of this killer virus, in China and elsewhere, becomes a standard and its prevalence is reduced through proper care and treatment."

The diagnostics business is focused on developing products for small to mid-size laboratories, including advanced genomic solutions that are being introduced to the market.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Shipments of first units are expected to be started in the second half of 2015, with the group targeting hospitals in the Shanghai province. Upon completion of this, the group intends to begin sales and marketing efforts to other provinces in China.

The diagnostics business offers solution to the group, which is targeting markets where many laboratories are mid-sized and dispersed in different localities.